Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Immuneering from sell to hold, adding to a mixed but generally constructive analyst backdrop for the stock.
• Other analysts remain mostly positive: Cantor Fitzgerald started coverage with an overweight rating and a $17 price target, while Chardan Capital reiterated a buy with a $20 target. MarketBeat data shows an average rating of Moderate Buy and an average target price of $16.57.
• Immuneering shares were trading at $5.11, well below the consensus price target, after the company recently reported a quarterly loss of $0.21 per share that beat expectations. The company’s lead program, IRX-2, is in Phase 2 trials for painful diabetic peripheral neuropathy.

Immuneering (NASDAQ:IMRX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Sunday.

Several other equities analysts also recently issued reports on IMRX. Cantor Fitzgerald assumed coverage on shares of Immuneering in a research note on Wednesday. They set an "overweight" rating and a $17.00 price objective on the stock. Oppenheimer reiterated an "outperform" rating on shares of Immuneering in a report on Monday, June 1st. Weiss Ratings restated a "sell (d-)" rating on shares of Immuneering in a report on Wednesday, June 24th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Immuneering in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Immuneering has an average rating of "Moderate Buy" and an average target price of $16.57.

Immuneering Price Performance

Immuneering stock traded down $0.25 during mid-day trading on Friday, hitting $5.11. 827,746 shares of the company were exchanged, compared to its average volume of 1,456,130. The business's 50 day simple moving average is $4.86 and its two-hundred day simple moving average is $5.18. The company has a market capitalization of $330.62 million, a P/E ratio of -4.37 and a beta of 0.41. Immuneering has a 12-month low of $2.90 and a 12-month high of $10.08.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.09. Equities research analysts predict that Immuneering will post -1.09 earnings per share for the current year.

Institutional Trading of Immuneering

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Empery Asset Management LP purchased a new position in shares of Immuneering in the 4th quarter worth $17,601,000. Vanguard Group Inc. increased its stake in Immuneering by 128.5% during the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company's stock worth $16,907,000 after acquiring an additional 1,358,322 shares during the last quarter. State Street Corp increased its stake in Immuneering by 1,289.7% during the fourth quarter. State Street Corp now owns 2,402,238 shares of the company's stock worth $15,807,000 after acquiring an additional 2,229,374 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Immuneering by 10.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company's stock worth $13,121,000 after purchasing an additional 195,176 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Immuneering in the 3rd quarter valued at about $6,602,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.